The history and future of short‐acting beta<sub>2</sub>‐agonist therapy in asthma

Hills, Thomas; Beasley, Richard

doi:10.1111/resp.13727

Cited by 8 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhaled short-acting b 2 agonists (SABAs), including salbutamol, were developed in the 1950s and became the primary therapies for all asthma severities [1,2]. After it was established in the 1990s that asthma is a chronic inflammatory disease, inhaled corticosteroids (ICSs) were identified as the most effective anti-inflammatory treatment [3], and recommendations for SABA use were changed from 'regular' to 'asneeded' therapy for symptom relief [1,2]. The superior efficacy and safety of inhaled versus oral SABAs were also demonstrated in the 1990s [4], leading asthma guidelines to favor inhaled administration [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…The superior efficacy and safety of inhaled versus oral SABAs were also demonstrated in the 1990s [4], leading asthma guidelines to favor inhaled administration [5][6][7][8][9]. A regimen that combines inhaled SABA reliever for use as required with ICS-based regular maintenance therapy was proposed for patients with frequent symptoms to improve asthma control, reduce lung function deterioration, and prevent exacerbations [1,2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

Domingo

Singh

2023

Adv Ther

View full text Add to dashboard Cite

Short-acting b 2 agonists (SABAs) have been a mainstay of asthma treatment since the 1950s, and have been mainly recommended as-needed for symptom relief alongside daily inhaled corticosteroid (ICS)-based maintenance treatment for the past 30 years. However, patient adherence to regular ICS-based anti-inflammatory maintenance therapy is frequently poor, leading to SABA overuse for symptom relief and associated poor outcomes. At present, there is a lack of consensus between treatment guidelines on how SABA should be used, and as-needed ICS-formoterol is suggested by some as an alternative reliever therapy. Here, we examine the pharmacology and current use of inhaled SABAs, identify that regular dosing of ICS can encourage appropriate SABA use, and appraise the evidence used to support the changing reliever treatment recommendations. We conclude that SABA continues to play an important role in the asthma management landscape, and give our views on how it should be used in patients with mild-moderate asthma, to complement regular ICS-based maintenance treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

Domingo

Singh

2023

Adv Ther

View full text Add to dashboard Cite

show abstract

“…Current management of asthma involves use of medications to target relief of acute symptoms or provide long-term symptom control [1]. Short-acting b 2 -agonist (SABA) therapy has been the most widely used rescue medication for relief of acute asthma symptoms since the 1950s [2][3][4] with salbutamol (also referred to as albuterol) introduced in 1968 [4]. However, since 2019 the Global Initiative for Asthma (GINA) has moved away from recommending SABA as the preferred option for reliever therapy, either alone or in conjunction with inhaled corticosteroid (ICS) maintenance therapy [5,6].…”

Section: Introductionmentioning

confidence: 99%

Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis

et al. 2022

View full text Add to dashboard Cite

Introduction: Short-acting b 2 -agonist (SABA) reliever overuse is common in asthma, despite availability of inhaled corticosteroid (ICS)-based maintenance therapies, and may be associated with increased risk of adverse events (AEs). This systematic literature review (SLR) and meta-analysis aimed to investigate the safety and tolerability of SABA reliever monotherapy for adults and adolescents with asthma, through analysis of randomized controlled trials (RCTs) and real-world evidence. Methods: An SLR of English-language publications between January 1996 and December 2021 included RCTs and observational studies of patients aged C 12 years treated with inhaled SABA reliever monotherapy (fixed dose or as needed) for C 4 weeks. Studies of terbutaline and fenoterol were excluded. Meta-analysis feasibility was dependent on cross-trial data

show abstract

“…People with asthma can lead a normal life if timely and adequate intervention is available. Although, asthma treatment landscape has come a long way from the short-acting beta-agonist (SABA) epidemic of the 1960s, asthma still contributes to significant economic burden on the healthcare resources [5,[9][10][11]. In the latest Global Asthma Report, asthma ranked 16th among the leading causes of years lived with disability (YLD) and 28th among the leading causes of burden of disease, as measured by disability adjusted life years (DALYs) [5].…”

Section: Introductionmentioning

confidence: 99%

Burden and unmet needs in asthma care in the Asia‐Pacific region

Wadhawan¹,

Muthukumaru

Loh

2022

Public Health Challenges

View full text Add to dashboard Cite

Asthma is a chronic respiratory disease with increasing global prevalence. It affects approximately 300 million people globally and more than a third of these patients have uncontrolled asthma. The burden of poorly controlled asthma is considerable both for the individuals and the society. The World Health Organization (WHO) estimates that, 455,000 people died from asthma worldwide in 2019, the majority in low and low‐middle‐income countries. This article highlights the unmet needs and burden of asthma in the Asia‐Pacific region where many patients have poorly controlled asthma despite advances in asthma care and treatment. A mismatch between patients’ (and physicians’) perception of asthma control and optimal asthma control as defined by the Global Initiative for Asthma (GINA) is a challenge in the real‐life management of many patients. Consequently, treatment adherence and optimization are affected. In many of these aspects, patients with asthma in the Asia‐Pacific region are comparatively worse than those from Europe and North America. In future, cooperation of all stakeholders is needed in improving awareness, education, and goal‐directed management of asthma with meaningful improvement in quality of life. This article draws attention to some of the important gaps in asthma management in the Asia‐Pacific region and suggests some measures to address these unmet needs.

show abstract

The history and future of short‐acting beta₂‐agonist therapy in asthma

Cited by 8 publications

References 13 publications

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis

Burden and unmet needs in asthma care in the Asia‐Pacific region

Contact Info

Product

Resources

About

The history and future of short‐acting beta2‐agonist therapy in asthma

Cited by 8 publications

References 13 publications

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis

Burden and unmet needs in asthma care in the Asia‐Pacific region

Contact Info

Product

Resources

About

The history and future of short‐acting beta₂‐agonist therapy in asthma